clinical trial · NCT01638000
A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.
Astellas Pharma Europe Ltd.·phase3·completed·n = 1,887
Urologic DiseasesUrinary Bladder, OveractiveUrinary Bladder DiseasesMirabegronSolifenacin succinate
brief summary
The purpose of the study was to assess the efficacy, safety and tolerability of mirabegron 50 mg versus (vs) solifenacin 5 mg in the treatment of patients with OAB who were dissatisfied with their treatment due to lack of efficacy.
started
Jun 12, 2012
primary completion
Apr 24, 2013
completion
Apr 24, 2013
last updated
Nov 21, 2024
official title
A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol